Addus HomeCare (NASDAQ:ADUS) Price Target Raised to $101.00

Addus HomeCare (NASDAQ:ADUS) had its price objective upped by Barclays from $96.00 to $101.00 in a report issued on Wednesday morning,Benzinga reports. They currently have an underweight rating on the stock.

ADUS has been the subject of a number of other reports. Bank of America cut shares of Addus HomeCare from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $140.00 to $125.00 in a research note on Monday, September 14th. Weiss Ratings upgraded Addus HomeCare from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Royal Bank Of Canada increased their target price on Addus HomeCare from $130.00 to $134.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Citigroup downgraded Addus HomeCare from a “market outperform” rating to a “neutral” rating in a research report on Monday, September 14th. Finally, Raymond James Financial set a $137.00 price target on Addus HomeCare in a report on Monday, September 28th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Addus HomeCare has a consensus rating of “Moderate Buy” and a consensus target price of $134.70.

Addus HomeCare Price Performance

Shares of Addus HomeCare stock traded down $2.50 on Wednesday, hitting $124.31. The company’s stock had a trading volume of 276,627 shares, compared to its average volume of 212,662. The company has a market capitalization of $2.32 billion, a P/E ratio of 20.72, a price-to-earnings-growth ratio of 1.79 and a beta of 0.75. Addus HomeCare has a 52-week low of $87.95 and a 52-week high of $131.59. The firm has a fifty day moving average price of $117.60 and a 200-day moving average price of $106.88. The company has a quick ratio of 1.69, a current ratio of 1.69 and a debt-to-equity ratio of 0.05.

Addus HomeCare (NASDAQ:ADUS) last posted its earnings results on Tuesday, November 3rd. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.04. The firm had revenue of $387.74 million during the quarter, compared to the consensus estimate of $388.72 million. Addus HomeCare had a net margin of 7.13% and a return on equity of 9.96%. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the firm posted $1.56 EPS. On average, equities research analysts expect that Addus HomeCare will post 6.34 earnings per share for the current fiscal year.

Institutional Trading of Addus HomeCare

A number of hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Addus HomeCare in the 2nd quarter valued at $344,153,000. Dimensional Fund Advisors LP boosted its holdings in shares of Addus HomeCare by 11.8% during the first quarter. Dimensional Fund Advisors LP now owns 744,127 shares of the company’s stock worth $69,689,000 after purchasing an additional 78,415 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Addus HomeCare during the second quarter worth $35,527,000. TimesSquare Capital Management LLC purchased a new stake in shares of Addus HomeCare in the second quarter valued at $31,502,000. Finally, Punch & Associates Investment Management Inc. purchased a new stake in shares of Addus HomeCare in the second quarter valued at $20,911,000. Institutional investors and hedge funds own 95.35% of the company’s stock.

Addus HomeCare News Summary

Here are the key news stories impacting Addus HomeCare this week:

• Positive Sentiment: UBS raised its price target to $160 from $145 and maintained a Buy rating; TD Cowen lifted its target to $145 from $131 and also maintained a Buy rating. UBS price-target report TD Cowen price-target report
• Positive Sentiment: ADUS recently reached a 52-week high. Its latest quarterly results included earnings per share of $1.83, ahead of the $1.79 consensus, while revenue increased 7% year over year. Addus hits a 12-month high
• Positive Sentiment: The company said it expects to close its AccentCare acquisition in the first quarter of 2027 and anticipates a full-year adjusted EBITDA margin around 13%; the deal may offer a growth opportunity, though execution remains ahead. AccentCare update
• Neutral Sentiment: Recent Zacks pieces discuss ADUS’s momentum and value-investing appeal, but the available summaries do not provide specific ratings or new estimates. Zacks momentum article Zacks value article
• Negative Sentiment: Quarterly revenue of $387.74 million was slightly below analysts’ $388.72 million estimate, tempering the otherwise positive earnings beat. Q3 earnings call highlights

Addus HomeCare Company Profile

Addus HomeCare Inc (NASDAQ: ADUS) provides in-home personal care, hospice and home health services to older adults, people with disabilities and other individuals who need assistance with daily living or medical care. Its services are designed to help clients remain safely and independently in their homes while supporting families and caregivers.

The company’s personal care services include assistance with bathing, dressing, grooming, meal preparation, housekeeping and other activities of daily living.